States Take Drug Makers to Court Over Marketing
Authorities in some U.S. states have become more aggressive in accusing drug makers of deceptive marketing, widening the potential liability for an industry that has shelled out billions of dollars to settle investigations led by the federal government.
See all stories on this topic »
Chief Digital Officer (CDO): Technology + Marketing = New …
What exacty is a Chief Digital Officer (CDO), and what does one actually do?ReadWrite
See all stories on this topic »
Marketing firm CEO with court record was big Obama inaugural donor
Records released Monday show that Marliem, CEO and founder of the Marliem Marketing Group in Minneapolis, made donations of $100,000 and $125,000 to the Presidential Inaugural Committee in January. The Federal Election Commission also shows …
See all stories on this topic »
Popular Questions
Why are states taking drug makers to court over marketing practices?
States are suing drug makers when they believe promotional campaigns misrepresented a medicine’s benefits, minimized its risks, or encouraged inappropriate use. These cases often focus on whether marketing influenced doctors, patients, or distributors in ways that contributed to public harm. State attorneys general may seek financial penalties, reimbursement for public costs, and changes to future advertising practices.
What marketing claims are states examining in lawsuits against drug companies?
Legal complaints may examine statements about a drug’s safety, effectiveness, addictive potential, side effects, or appropriate patient population. Investigators can review advertisements, sales-training materials, sponsored research, payments to medical professionals, and communications with prescribers. Companies may face greater scrutiny when internal records appear inconsistent with public promotional claims.
How could states taking drug makers to court over marketing affect consumers?
Settlements or court rulings can require clearer risk disclosures, limits on promotional messaging, and monitoring of sales practices. The proceedings may also help states recover money spent on treatment, prevention, enforcement, and other consequences linked to allegedly misleading marketing. Consumers should still rely on licensed clinicians, official prescribing information, and independent medical advice rather than promotional claims alone.